FDA reviewers back similarity of Sandoz's Enbrel biosimilar

In GP2015 from the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) to its U.S.-licensed reference product, Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN). The reviewers also said Sandoz had provided extensive

Read the full 301 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE